Introduction
A common clinical dilemma regarding elderly women with advanced breast cancer is the choice of chemotherapy, as approximately 50% of diagnoses occur after age 65 and few clinical trials have studied aged patients [1] [2] [3] [4] . Treatment of elderly can be challenging due to comorbidity, risk of toxicity, and reduced quality of life. For these reasons, single-agent therapy is generally advocated [5, 6] . Evaluating different chemotherapy regimens for elderly women with breast cancer should include investigating factors that could facilitate selection of patients with the best chance of treatment benefit. Efficacy and toxicity are influenced by both host and tumor factors, which may include the expression of P-glycoprotein (encoded by the ABCB1 gene) and DNA repair proteins [7] .
Anthracyclines are among the most active agents for the treatment of breast cancer, but are limited by toxicities including myelosuppression, mucositis, nausea and vomiting, and of special concern in the elderly, cardiotoxicity [2, 8] . Pegylated liposomal doxorubicin (PLD) is a liposomal encapsulated form of doxorubicin with a longer halflife, higher tumor tissue penetration, and reduced toxicity [9] . A large phase III study demonstrated PLD to have similar efficacy, improved cardiac safety, and a lower incidence of alopecia, nausea, vomiting, and myelosuppression compared with conventional doxorubicin as first-line treatment of metastatic breast cancer (MBC) [9] .
However, PLD was associated with a higher incidence of palmar-plantar erythrodysesthesia (PPE) and mucositis. A reduction of PLD from standard dose 50 mg/m 2 to 40 mg/m 2 resulted in comparable efficacy, but reduced incidence of PPE in a prospective phase II trial [8, 18] .
The aim of this study was to investigate the efficacy and safety of single-agent PLD 40 mg/m 2 as first-line treatment for elderly women with breast cancer, either locally-advanced or metastatic, and to search for predictive markers for treatment response and toxicity. These included single nucleotide polymorphisms (SNPs) of the ABCB1 gene and tumor tissue investigations for the drug-related target topoisomerase IIα (TOPOIIa) and the MRE11/RAD50/NSB1 (MRN) complex involved in DNA repair [10] . /L, and a hemoglobin >90g/L was required as was a life expectancy of ≥12 weeks. All patients received oral and written information, and provided written informed consent.
Materials and Methods

Eligibility Criteria
Major exclusion criteria included previous chemotherapy for MBC, recurrence <12 months after adjuvant anthracycline, myocardial infarction within 6 months of planned inclusion, and symptomatic brain metastasis. Patients eligible for trastuzumab or endocrine therapy were excluded.
The study was approved by the Ethics Committee at the University Hospital in Linköping, Sweden (M172-06), and the trial was registered at www.clinical trials.gov (NCT 0060 4968).
Study Design
This was a multicenter, open, single-arm, phase IV study. Patients received PLD 40 mg/m 2 intravenously every four weeks. Dose modifications were permitted for hematologic and non-hematologic toxicity. Treatment was continued until progression, unacceptable toxicity, or by physician or patient decision to withdraw from the study.
Efficacy and safety were assessed.
Study Objectives
The primary endpoint of the study was time to treatment failure (TTF [11, 12] . Both RECIST and WHO criteria were used for patients with measurable disease and bone metastases.
Tumor evaluation was performed by radiology and physical examination at baseline and every 12 weeks after the start of treatment. Radiological procedures included a computerized tomography (CT) or ultrasound of the abdomen, CT or x-ray of the thorax, bone scan and x-ray of hot spots.
Safety Measurements
All adverse events (AEs) were graded according to NCI Common Terminology
Criteria for Adverse Events (CTCAE) version 3.0 [13] . Serious AEs (SAEs) were defined as any adverse drug or biologic experience occurring at any dose resulting in death, lifethreatening AEs, persistent or significant disability/incapacity, or in-patient hospitalization.
Cardiac monitoring was by ultrasonic echocardiography (UCG) with calculation of LVEF, and was performed every 12 weeks for patients having previously received anthracyclines and every 6 months for anthracycline-naïve patients. Once patients minutes at room temperature. The immunostaining was visualized using 3, 3'-diaminobenzidine and hydrogen peroxide for 8 minutes. After washing, the slides were counterstained with hematoxylin, dehydrated, and mounted.
Evaluation of Immunostaining
The immunohistochemical staining was evaluated independently by two investigators blinded to clinical data. In cases of discrepant scoring, a consensus score was reached after re-evaluation. For the MRN proteins, a proportion score, representing the estimated proportion of stained cell nuclei (0=no stained cell nuclei; 1=1-25%;
2=26-50%; 3=51-75%; 4=76-100%) and an intensity score, representing the intensity of the stained cell nuclei (0=no staining; 1=weak staining; 2=moderate staining; 3=strong staining) was assigned. For TOPOIIa, the proportion score was slightly different (0=<10%; 1=11-25%; 2=26-50%; 3=51-75%; 4=76-100%). The proportion and intensity scores were then added to obtain a total score, ranging from 0-7.
Genotyping of ABCB1
Genomic DNA was isolated from whole blood using the Maxwell 16 blood DNA purification kit from Promega (Madison, WI, USA). The genotypes for the ABCB1 SNPs G1199A, C1236T, G2677T/A, and C3435T were determined using pyrosequencing as previously described [14, 15] . In short, a HotStarTaq master mixture (VWR International, Stockholm, Sweden) was used for PCR amplification, and all reactions were carried out on a Mastercycler gradient instrument (Eppendorf, Germany) in a total volume of 25 µL.
The SNPs were analyzed using a Pyrosequencing PSQ96MA instrument (Qiagen, Stockholm, Sweden) according to the manufacturer's protocol by annealing a specific sequencing primer to a single stranded PCR-product and dispensing single nucleotides in a predesigned order [14, 15] .
Statistical Methods
The primary endpoint, median TTF, was assumed to be 7 months. A sample size of 25 patients was expected to produce a 95% confidence interval (CI) of 3.6-12 months. TTF was measured from date of first treatment to date of event and censored for patients with no event at the date of last visit. TTF, TTP, and OS were calculated by using the Kaplan-Meier estimate and log-rank test when comparing subgroups of patients.
Response and progression were defined as the first evaluation that showed response or progression, respectively. Response had to be confirmed by two observations not less than 4 weeks apart. Duration of response was defined as the time span between first response and first progression. enrolled patients, three had non-measurable disease and were not included in the response analysis. They were withdrawn from the study without documented progression after 6, 7, and 11 cycles, respectively. Eighteen patients were assessed by RECIST or a combination of RECIST and WHO criteria, and four by WHO criteria only.
Results
Patient Demographics
Of these, three achieved a PR, and 13 had SD; six had PD as best response. Six of the 16 patients with SD or non-measurable disease received ≥7 cycles of therapy, resulting in 6 months or longer disease stabilization.
Safety
Patients received a median of 6 cycles and mean of 7.4 cycles (range 1-21 cycles) of therapy. The majority of AEs were mild to moderate in severity and transient; no grade 3-4 hematologic toxicities were noted. The main related toxicities (all grades)
were nausea (60%), fatigue (56%), and PPE (52%) ( Table 2 -grade 3 and 4 toxicity).
Four SAEs were reported possibly related to PLD.
Clinically significant cardiac events were noted in three patients: one grade 2 heart valve dysfunction and grade 1 left ventricular dysfunction; one grade 4 myocardial infarction and heart failure; and one grade 2 tachycardia, the latter two leading to PLD discontinuation. Four decreases in LVEF did not meet criteria for study withdrawal.
Study drug was also discontinued in two patients due to severe PPE. PLD dose was reduced in 10 patients, six due to weight loss and four due to: PPE(2), rash(1), and diarrhea(1).
Single Nucleotide Polymorphism in ABCB1 Gene
Twenty-four patients were genotyped for the ABCB1 SNPs (Table 3) . One patient with a G/A genotype of G2677T/A was excluded from further analysis. For the variant G1199A, only 1 patient had the G/A genotype, and this SNP was not evaluated for clinical response. TTF by ABCB1 genotypes G2677T and C3435T are shown in Figure   1 , and the genotype effects on TTP are shown in Figure 2 . The mean TTF and mean TTP for the ABCB1 genotypes are presented in Table 3 . The estimated mean TTF and TTP were significantly longer for patients who were wild type for G2677T, intermediate The findings regarding the MRN score and TOPOIIα were largely independent of other prognostic tumor characteristics, such as grade and hormone receptor status (data not shown).
Discussion
The optimal treatment for women over 65 years with locally advanced or MBC has not yet been determined. Exploring the role of different chemotherapeutic agents in this setting via clinical trials is necessary for evidence-based treatment recommendations.
Identifying predictive markers for chemotherapy is becoming increasingly important to optimize treatment efficacy and diminish patient suffering due to toxicity. Despite few objective responses, OS of 20.6 months was comparable to that observed in the O`Brien study. TTP was 5.7 months, which is also similar to the other first line studies (range 5.4-6.9 months) using higher dosing (Table 4 ).
The use of single-agent chemotherapy in our study facilitated identifying important biomarkers that may correlate to outcome or AEs. In the ABCB1 genotype analysis, the G2677T genotype had a significant impact on TTF and TTP and C3435T had a nonsignificant trend on TTF and TTP (Figures 1 and 2 ). TTF and TTP were longest for patients with the wild-type genotype, intermediate for those being heterozygous, and shortest for homozygous variant patients. The G2677T genetic variation results in an amino-acid change from an alanine residue to a serine in P-glycoprotein at position 893, while the C3435T SNP is silent. Due to the fact that the G2677T and C3435T SNPs are linked, our findings corroborate results from Cizmarikova et al [19] who found that patients with the 3435C/C genotype had a longer TTP and an enhanced therapeutic outcome after neoadjuvant anthracycline-based chemotherapy. In accordance, Turgut et al [20] showed a trend toward a shorter PFS for breast cancer patients with 3435T/T compared to heterozygous and wild-type patients. They found no correlation between ABCB1 genotype and response, as also demonstrated by Rodrigues et al [21] .
Patients with the ABCB1 C3435T/T genotype were significantly more susceptible to moderate to severe PPE affecting 62% of patients compared to 12% of those with non-3435T/T genotype ( Figure 3) . PPE is believed to be due to PLD excretion through the skin; therefore, an enhanced efflux might promote this toxicity [22] . No correlation between myelosuppression or cardiotoxicity and ABCB1 was demonstrated.
Retrospective studies have shown that amplification of the gene encoding TOPOIIα (TOP2A) predicts sensitivity to anthracyclins [23] [24] [25] . As TOP2A amplification is almost exclusively found in tumors with HER2 amplification, and a positive HER2
status was an exclusion criterion in our study, we could not justify performing TOP2A
analysis with FISH. However, sensitivity to anthracycline-based therapy has also been related to high TOP2A expression levels and we hypothesized that high TOPOIIα levels, also in the absence of gene amplification, might be predictive [26] .
Immunohistochemical staining of TOPOIIα likely reflects abnormal expression of the protein, DNA replication, or both, and a positive correlation between TOPOIIα and Ki67 was observed. Accordingly, the TOPOIIα:Ki67 ratio more accurately predicted TTP than TOPOIIα alone.
The MRN complex is an active component in DNA double-strand break repair and may therefore play a role in chemotherapy effect. For cancer cells to resist treatment with drugs that fix topoisomerases to DNA, the topoisomerase must be released. Interestingly, MRN has been shown to be involved in topoisomerase removal,
suggesting that impaired MRN function may increase the half lives of DNAtopoisomerase complexes, leading to higher treatment efficiency [27, 28] . This might be a mechanistic explanation of our finding that patients with reduced MRN expression were less likely to progress.
In summary, our study demonstrated that PLD 40 mg/m 2 is a safe and effective treatment for elderly women with breast cancer. We found that SNPs of the ABCB1 gene correlate to both TTF and TTP and the risk of PPE, thereby indicating that the ABCB1 genotype could be a predictive factor for therapy with PLD in these patients. We also showed that expression of TOPOIIα and the MRN complex influenced treatment 
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